“Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s445, https://doi.org/10.25251/skin.8.supp.445.